http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 06 Mar 2026 11:22:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html <div class="xn-content"> <p><span class="legendSpanClass">UPPSALA, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&amp;D Day on <chron>March 24, 2026</chron>. The event will take place at the <span>Royal Swedish Academy of Engineering Sciences</span> (IVA), Grev Turegatan 16, <location value="LU/se..stholm" idsrc="xmltag.org" >Stockholm, Sweden</location>.</p> <p>During the day, CEO <person>Nikolaj Sørensen</person> and the management team will outline <span value="Stockholm:ORX" idsrc="xmltag.org" >Orexo's</span> updated strategy and R&amp;D priorities following the divestment of Zubsolv® in the US, including how the company's proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The http://www.streetinsider.com/Press+Releases/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html Fri, 06 Mar 2026 11:22:00 -0400 A.05250916 A.08652595 A.38925042 O.00620980 O.00624617 O.02090367 O.03285412 ORX ORX ORX.ST ORXOF ORXOY http://www.streetinsider.com/Press+Releases/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html <div class="xn-content"> <p><span class="legendSpanClass">UPPSALA, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&amp;D Day on <chron>March 24, 2026</chron>. The event will take place at the <span>Royal Swedish Academy of Engineering Sciences</span> (IVA), Grev Turegatan 16, <location value="LU/se..stholm" idsrc="xmltag.org" >Stockholm, Sweden</location>.</p> <p>During the day, CEO <person>Nikolaj Sørensen</person> and the management team will outline <span value="Stockholm:ORX" idsrc="xmltag.org" >Orexo's</span> updated strategy and R&amp;D priorities following the divestment of Zubsolv® in the US, including how the company's proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The http://www.streetinsider.com/Press+Releases/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html Fri, 06 Mar 2026 11:22:00 -0400 A.05250916 A.08652595 A.38925042 O.00620980 O.00624617 O.02090367 O.03285412 ORX ORX ORX.ST ORXOF ORXOY http://www.streetinsider.com/Press+Releases/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html <div class="xn-content"> <p><span class="legendSpanClass">UPPSALA, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&amp;D Day on <chron>March 24, 2026</chron>. The event will take place at the <span>Royal Swedish Academy of Engineering Sciences</span> (IVA), Grev Turegatan 16, <location value="LU/se..stholm" idsrc="xmltag.org" >Stockholm, Sweden</location>.</p> <p>During the day, CEO <person>Nikolaj Sørensen</person> and the management team will outline <span value="Stockholm:ORX" idsrc="xmltag.org" >Orexo's</span> updated strategy and R&amp;D priorities following the divestment of Zubsolv® in the US, including how the company's proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The http://www.streetinsider.com/Press+Releases/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html Fri, 06 Mar 2026 11:22:00 -0400 A.05250916 A.08652595 A.38925042 O.00620980 O.00624617 O.02090367 O.03285412 ORX ORX ORX.ST ORXOF ORXOY http://www.streetinsider.com/Press+Releases/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html <div class="xn-content"> <p><span class="legendSpanClass">UPPSALA, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&amp;D Day on <chron>March 24, 2026</chron>. The event will take place at the <span>Royal Swedish Academy of Engineering Sciences</span> (IVA), Grev Turegatan 16, <location value="LU/se..stholm" idsrc="xmltag.org" >Stockholm, Sweden</location>.</p> <p>During the day, CEO <person>Nikolaj Sørensen</person> and the management team will outline <span value="Stockholm:ORX" idsrc="xmltag.org" >Orexo's</span> updated strategy and R&amp;D priorities following the divestment of Zubsolv® in the US, including how the company's proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The http://www.streetinsider.com/Press+Releases/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html Fri, 06 Mar 2026 11:22:00 -0400 A.05250916 A.08652595 A.38925042 O.00620980 O.00624617 O.02090367 O.03285412 ORX ORX ORX.ST ORXOF ORXOY http://www.streetinsider.com/Press+Releases/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html <div class="xn-content"> <p><span class="legendSpanClass">UPPSALA, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&amp;D Day on <chron>March 24, 2026</chron>. The event will take place at the <span>Royal Swedish Academy of Engineering Sciences</span> (IVA), Grev Turegatan 16, <location value="LU/se..stholm" idsrc="xmltag.org" >Stockholm, Sweden</location>.</p> <p>During the day, CEO <person>Nikolaj Sørensen</person> and the management team will outline <span value="Stockholm:ORX" idsrc="xmltag.org" >Orexo's</span> updated strategy and R&amp;D priorities following the divestment of Zubsolv® in the US, including how the company's proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The http://www.streetinsider.com/Press+Releases/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html Fri, 06 Mar 2026 11:22:00 -0400 A.05250916 A.08652595 A.38925042 O.00620980 O.00624617 O.02090367 O.03285412 ORX ORX ORX.ST ORXOF ORXOY http://www.streetinsider.com/Press+Releases/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html <div class="xn-content"> <p><span class="legendSpanClass">UPPSALA, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&amp;D Day on <chron>March 24, 2026</chron>. The event will take place at the <span>Royal Swedish Academy of Engineering Sciences</span> (IVA), Grev Turegatan 16, <location value="LU/se..stholm" idsrc="xmltag.org" >Stockholm, Sweden</location>.</p> <p>During the day, CEO <person>Nikolaj Sørensen</person> and the management team will outline <span value="Stockholm:ORX" idsrc="xmltag.org" >Orexo's</span> updated strategy and R&amp;D priorities following the divestment of Zubsolv® in the US, including how the company's proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The http://www.streetinsider.com/Press+Releases/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html Fri, 06 Mar 2026 11:22:00 -0400 A.05250916 A.08652595 A.38925042 O.00620980 O.00624617 O.02090367 O.03285412 ORX ORX ORX.ST ORXOF ORXOY http://www.streetinsider.com/Press+Releases/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html <div class="xn-content"> <p><span class="legendSpanClass">UPPSALA, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&amp;D Day on <chron>March 24, 2026</chron>. The event will take place at the <span>Royal Swedish Academy of Engineering Sciences</span> (IVA), Grev Turegatan 16, <location value="LU/se..stholm" idsrc="xmltag.org" >Stockholm, Sweden</location>.</p> <p>During the day, CEO <person>Nikolaj Sørensen</person> and the management team will outline <span value="Stockholm:ORX" idsrc="xmltag.org" >Orexo's</span> updated strategy and R&amp;D priorities following the divestment of Zubsolv® in the US, including how the company's proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The http://www.streetinsider.com/Press+Releases/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html Fri, 06 Mar 2026 11:22:00 -0400 A.05250916 A.08652595 A.38925042 O.00620980 O.00624617 O.02090367 O.03285412 ORX ORX ORX.ST ORXOF ORXOY http://www.streetinsider.com/Press+Releases/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html <div class="xn-content"> <p><span class="legendSpanClass">UPPSALA, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&amp;D Day on <chron>March 24, 2026</chron>. The event will take place at the <span>Royal Swedish Academy of Engineering Sciences</span> (IVA), Grev Turegatan 16, <location value="LU/se..stholm" idsrc="xmltag.org" >Stockholm, Sweden</location>.</p> <p>During the day, CEO <person>Nikolaj Sørensen</person> and the management team will outline <span value="Stockholm:ORX" idsrc="xmltag.org" >Orexo's</span> updated strategy and R&amp;D priorities following the divestment of Zubsolv® in the US, including how the company's proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The http://www.streetinsider.com/Press+Releases/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html Fri, 06 Mar 2026 11:22:00 -0400 A.05250916 A.08652595 A.38925042 O.00620980 O.00624617 O.02090367 O.03285412 ORX ORX ORX.ST ORXOF ORXOY http://www.streetinsider.com/Press+Releases/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html <div class="xn-content"> <p><span class="legendSpanClass">UPPSALA, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&amp;D Day on <chron>March 24, 2026</chron>. The event will take place at the <span>Royal Swedish Academy of Engineering Sciences</span> (IVA), Grev Turegatan 16, <location value="LU/se..stholm" idsrc="xmltag.org" >Stockholm, Sweden</location>.</p> <p>During the day, CEO <person>Nikolaj Sørensen</person> and the management team will outline <span value="Stockholm:ORX" idsrc="xmltag.org" >Orexo's</span> updated strategy and R&amp;D priorities following the divestment of Zubsolv® in the US, including how the company's proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The http://www.streetinsider.com/Press+Releases/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html Fri, 06 Mar 2026 11:22:00 -0400 A.05250916 A.08652595 A.38925042 O.00620980 O.00624617 O.02090367 O.03285412 ORX ORX ORX.ST ORXOF ORXOY http://www.streetinsider.com/Press+Releases/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html <div class="xn-content"> <p><span class="legendSpanClass">UPPSALA, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&amp;D Day on <chron>March 24, 2026</chron>. The event will take place at the <span>Royal Swedish Academy of Engineering Sciences</span> (IVA), Grev Turegatan 16, <location value="LU/se..stholm" idsrc="xmltag.org" >Stockholm, Sweden</location>.</p> <p>During the day, CEO <person>Nikolaj Sørensen</person> and the management team will outline <span value="Stockholm:ORX" idsrc="xmltag.org" >Orexo's</span> updated strategy and R&amp;D priorities following the divestment of Zubsolv® in the US, including how the company's proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The http://www.streetinsider.com/Press+Releases/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html Fri, 06 Mar 2026 11:22:00 -0400 A.05250916 A.08652595 A.38925042 O.00620980 O.00624617 O.02090367 O.03285412 ORX ORX ORX.ST ORXOF ORXOY http://www.streetinsider.com/Press+Releases/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html <div class="xn-content"> <p><span class="legendSpanClass">UPPSALA, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&amp;D Day on <chron>March 24, 2026</chron>. The event will take place at the <span>Royal Swedish Academy of Engineering Sciences</span> (IVA), Grev Turegatan 16, <location value="LU/se..stholm" idsrc="xmltag.org" >Stockholm, Sweden</location>.</p> <p>During the day, CEO <person>Nikolaj Sørensen</person> and the management team will outline <span value="Stockholm:ORX" idsrc="xmltag.org" >Orexo's</span> updated strategy and R&amp;D priorities following the divestment of Zubsolv® in the US, including how the company's proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The http://www.streetinsider.com/Press+Releases/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html Fri, 06 Mar 2026 11:22:00 -0400 A.05250916 A.08652595 A.38925042 O.00620980 O.00624617 O.02090367 O.03285412 ORX ORX ORX.ST ORXOF ORXOY http://www.streetinsider.com/Press+Releases/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html <div class="xn-content"> <p><span class="legendSpanClass">UPPSALA, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&amp;D Day on <chron>March 24, 2026</chron>. The event will take place at the <span>Royal Swedish Academy of Engineering Sciences</span> (IVA), Grev Turegatan 16, <location value="LU/se..stholm" idsrc="xmltag.org" >Stockholm, Sweden</location>.</p> <p>During the day, CEO <person>Nikolaj Sørensen</person> and the management team will outline <span value="Stockholm:ORX" idsrc="xmltag.org" >Orexo's</span> updated strategy and R&amp;D priorities following the divestment of Zubsolv® in the US, including how the company's proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The http://www.streetinsider.com/Press+Releases/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html Fri, 06 Mar 2026 11:22:00 -0400 A.05250916 A.08652595 A.38925042 O.00620980 O.00624617 O.02090367 O.03285412 ORX ORX ORX.ST ORXOF ORXOY http://www.streetinsider.com/Press+Releases/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html <div class="xn-content"> <p><span class="legendSpanClass">UPPSALA, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&amp;D Day on <chron>March 24, 2026</chron>. The event will take place at the <span>Royal Swedish Academy of Engineering Sciences</span> (IVA), Grev Turegatan 16, <location value="LU/se..stholm" idsrc="xmltag.org" >Stockholm, Sweden</location>.</p> <p>During the day, CEO <person>Nikolaj Sørensen</person> and the management team will outline <span value="Stockholm:ORX" idsrc="xmltag.org" >Orexo's</span> updated strategy and R&amp;D priorities following the divestment of Zubsolv® in the US, including how the company's proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The http://www.streetinsider.com/Press+Releases/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html Fri, 06 Mar 2026 11:22:00 -0400 A.05250916 A.08652595 A.38925042 O.00620980 O.00624617 O.02090367 O.03285412 ORX ORX ORX.ST ORXOF ORXOY http://www.streetinsider.com/PRNewswire/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html <div class="xn-content"> <p><span class="legendSpanClass">UPPSALA, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&amp;D Day on <chron>March 24, 2026</chron>. The event will take place at the <span>Royal Swedish Academy of Engineering Sciences</span> (IVA), Grev Turegatan 16, <location value="LU/se..stholm" idsrc="xmltag.org" >Stockholm, Sweden</location>.</p> <p>During the day, CEO <person>Nikolaj Sørensen</person> and the management team will outline <span value="Stockholm:ORX" idsrc="xmltag.org" >Orexo's</span> updated strategy and R&amp;D priorities following the divestment of Zubsolv® in the US, including how the company's proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The http://www.streetinsider.com/PRNewswire/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html Fri, 06 Mar 2026 11:22:00 -0400 A.05250916 A.08652595 A.38925042 O.00620980 O.00624617 O.02090367 O.03285412 ORX ORX ORX.ST ORXOF ORXOY http://www.streetinsider.com/PRNewswire/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html <div class="xn-content"> <p><span class="legendSpanClass">UPPSALA, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&amp;D Day on <chron>March 24, 2026</chron>. The event will take place at the <span>Royal Swedish Academy of Engineering Sciences</span> (IVA), Grev Turegatan 16, <location value="LU/se..stholm" idsrc="xmltag.org" >Stockholm, Sweden</location>.</p> <p>During the day, CEO <person>Nikolaj Sørensen</person> and the management team will outline <span value="Stockholm:ORX" idsrc="xmltag.org" >Orexo's</span> updated strategy and R&amp;D priorities following the divestment of Zubsolv® in the US, including how the company's proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The http://www.streetinsider.com/PRNewswire/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html Fri, 06 Mar 2026 11:22:00 -0400 A.05250916 A.08652595 A.38925042 O.00620980 O.00624617 O.02090367 O.03285412 ORX ORX ORX.ST ORXOF ORXOY http://www.streetinsider.com/PRNewswire/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html <div class="xn-content"> <p><span class="legendSpanClass">UPPSALA, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&amp;D Day on <chron>March 24, 2026</chron>. The event will take place at the <span>Royal Swedish Academy of Engineering Sciences</span> (IVA), Grev Turegatan 16, <location value="LU/se..stholm" idsrc="xmltag.org" >Stockholm, Sweden</location>.</p> <p>During the day, CEO <person>Nikolaj Sørensen</person> and the management team will outline <span value="Stockholm:ORX" idsrc="xmltag.org" >Orexo's</span> updated strategy and R&amp;D priorities following the divestment of Zubsolv® in the US, including how the company's proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The http://www.streetinsider.com/PRNewswire/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html Fri, 06 Mar 2026 11:22:00 -0400 A.05250916 A.08652595 A.38925042 O.00620980 O.00624617 O.02090367 O.03285412 ORX ORX ORX.ST ORXOF ORXOY http://www.streetinsider.com/PRNewswire/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html <div class="xn-content"> <p><span class="legendSpanClass">UPPSALA, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&amp;D Day on <chron>March 24, 2026</chron>. The event will take place at the <span>Royal Swedish Academy of Engineering Sciences</span> (IVA), Grev Turegatan 16, <location value="LU/se..stholm" idsrc="xmltag.org" >Stockholm, Sweden</location>.</p> <p>During the day, CEO <person>Nikolaj Sørensen</person> and the management team will outline <span value="Stockholm:ORX" idsrc="xmltag.org" >Orexo's</span> updated strategy and R&amp;D priorities following the divestment of Zubsolv® in the US, including how the company's proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The http://www.streetinsider.com/PRNewswire/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html Fri, 06 Mar 2026 11:22:00 -0400 A.05250916 A.08652595 A.38925042 O.00620980 O.00624617 O.02090367 O.03285412 ORX ORX ORX.ST ORXOF ORXOY http://www.streetinsider.com/PRNewswire/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html <div class="xn-content"> <p><span class="legendSpanClass">UPPSALA, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&amp;D Day on <chron>March 24, 2026</chron>. The event will take place at the <span>Royal Swedish Academy of Engineering Sciences</span> (IVA), Grev Turegatan 16, <location value="LU/se..stholm" idsrc="xmltag.org" >Stockholm, Sweden</location>.</p> <p>During the day, CEO <person>Nikolaj Sørensen</person> and the management team will outline <span value="Stockholm:ORX" idsrc="xmltag.org" >Orexo's</span> updated strategy and R&amp;D priorities following the divestment of Zubsolv® in the US, including how the company's proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The http://www.streetinsider.com/PRNewswire/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html Fri, 06 Mar 2026 11:22:00 -0400 A.05250916 A.08652595 A.38925042 O.00620980 O.00624617 O.02090367 O.03285412 ORX ORX ORX.ST ORXOF ORXOY http://www.streetinsider.com/PRNewswire/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html <div class="xn-content"> <p><span class="legendSpanClass">UPPSALA, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&amp;D Day on <chron>March 24, 2026</chron>. The event will take place at the <span>Royal Swedish Academy of Engineering Sciences</span> (IVA), Grev Turegatan 16, <location value="LU/se..stholm" idsrc="xmltag.org" >Stockholm, Sweden</location>.</p> <p>During the day, CEO <person>Nikolaj Sørensen</person> and the management team will outline <span value="Stockholm:ORX" idsrc="xmltag.org" >Orexo's</span> updated strategy and R&amp;D priorities following the divestment of Zubsolv® in the US, including how the company's proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The http://www.streetinsider.com/PRNewswire/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html Fri, 06 Mar 2026 11:22:00 -0400 A.05250916 A.08652595 A.38925042 O.00620980 O.00624617 O.02090367 O.03285412 ORX ORX ORX.ST ORXOF ORXOY http://www.streetinsider.com/PRNewswire/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html <div class="xn-content"> <p><span class="legendSpanClass">UPPSALA, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&amp;D Day on <chron>March 24, 2026</chron>. The event will take place at the <span>Royal Swedish Academy of Engineering Sciences</span> (IVA), Grev Turegatan 16, <location value="LU/se..stholm" idsrc="xmltag.org" >Stockholm, Sweden</location>.</p> <p>During the day, CEO <person>Nikolaj Sørensen</person> and the management team will outline <span value="Stockholm:ORX" idsrc="xmltag.org" >Orexo's</span> updated strategy and R&amp;D priorities following the divestment of Zubsolv® in the US, including how the company's proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The http://www.streetinsider.com/PRNewswire/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html Fri, 06 Mar 2026 11:22:00 -0400 A.05250916 A.08652595 A.38925042 O.00620980 O.00624617 O.02090367 O.03285412 ORX ORX ORX.ST ORXOF ORXOY http://www.streetinsider.com/PRNewswire/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html <div class="xn-content"> <p><span class="legendSpanClass">UPPSALA, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&amp;D Day on <chron>March 24, 2026</chron>. The event will take place at the <span>Royal Swedish Academy of Engineering Sciences</span> (IVA), Grev Turegatan 16, <location value="LU/se..stholm" idsrc="xmltag.org" >Stockholm, Sweden</location>.</p> <p>During the day, CEO <person>Nikolaj Sørensen</person> and the management team will outline <span value="Stockholm:ORX" idsrc="xmltag.org" >Orexo's</span> updated strategy and R&amp;D priorities following the divestment of Zubsolv® in the US, including how the company's proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The http://www.streetinsider.com/PRNewswire/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html Fri, 06 Mar 2026 11:22:00 -0400 A.05250916 A.08652595 A.38925042 O.00620980 O.00624617 O.02090367 O.03285412 ORX ORX ORX.ST ORXOF ORXOY http://www.streetinsider.com/PRNewswire/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html <div class="xn-content"> <p><span class="legendSpanClass">UPPSALA, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&amp;D Day on <chron>March 24, 2026</chron>. The event will take place at the <span>Royal Swedish Academy of Engineering Sciences</span> (IVA), Grev Turegatan 16, <location value="LU/se..stholm" idsrc="xmltag.org" >Stockholm, Sweden</location>.</p> <p>During the day, CEO <person>Nikolaj Sørensen</person> and the management team will outline <span value="Stockholm:ORX" idsrc="xmltag.org" >Orexo's</span> updated strategy and R&amp;D priorities following the divestment of Zubsolv® in the US, including how the company's proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The http://www.streetinsider.com/PRNewswire/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html Fri, 06 Mar 2026 11:22:00 -0400 A.05250916 A.08652595 A.38925042 O.00620980 O.00624617 O.02090367 O.03285412 ORX ORX ORX.ST ORXOF ORXOY http://www.streetinsider.com/PRNewswire/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html <div class="xn-content"> <p><span class="legendSpanClass">UPPSALA, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&amp;D Day on <chron>March 24, 2026</chron>. The event will take place at the <span>Royal Swedish Academy of Engineering Sciences</span> (IVA), Grev Turegatan 16, <location value="LU/se..stholm" idsrc="xmltag.org" >Stockholm, Sweden</location>.</p> <p>During the day, CEO <person>Nikolaj Sørensen</person> and the management team will outline <span value="Stockholm:ORX" idsrc="xmltag.org" >Orexo's</span> updated strategy and R&amp;D priorities following the divestment of Zubsolv® in the US, including how the company's proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The http://www.streetinsider.com/PRNewswire/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html Fri, 06 Mar 2026 11:22:00 -0400 A.05250916 A.08652595 A.38925042 O.00620980 O.00624617 O.02090367 O.03285412 ORX ORX ORX.ST ORXOF ORXOY http://www.streetinsider.com/PRNewswire/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html <div class="xn-content"> <p><span class="legendSpanClass">UPPSALA, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&amp;D Day on <chron>March 24, 2026</chron>. The event will take place at the <span>Royal Swedish Academy of Engineering Sciences</span> (IVA), Grev Turegatan 16, <location value="LU/se..stholm" idsrc="xmltag.org" >Stockholm, Sweden</location>.</p> <p>During the day, CEO <person>Nikolaj Sørensen</person> and the management team will outline <span value="Stockholm:ORX" idsrc="xmltag.org" >Orexo's</span> updated strategy and R&amp;D priorities following the divestment of Zubsolv® in the US, including how the company's proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The http://www.streetinsider.com/PRNewswire/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html Fri, 06 Mar 2026 11:22:00 -0400 A.05250916 A.08652595 A.38925042 O.00620980 O.00624617 O.02090367 O.03285412 ORX ORX ORX.ST ORXOF ORXOY http://www.streetinsider.com/PRNewswire/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html <div class="xn-content"> <p><span class="legendSpanClass">UPPSALA, <location value="LC/se" idsrc="xmltag.org" >Sweden</location></span>, <span class="legendSpanClass"><chron>March 6, 2026</chron></span> /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&amp;D Day on <chron>March 24, 2026</chron>. The event will take place at the <span>Royal Swedish Academy of Engineering Sciences</span> (IVA), Grev Turegatan 16, <location value="LU/se..stholm" idsrc="xmltag.org" >Stockholm, Sweden</location>.</p> <p>During the day, CEO <person>Nikolaj Sørensen</person> and the management team will outline <span value="Stockholm:ORX" idsrc="xmltag.org" >Orexo's</span> updated strategy and R&amp;D priorities following the divestment of Zubsolv® in the US, including how the company's proprietary drug delivery technology, AmorphOX®, underpins and drives its future development focus. The http://www.streetinsider.com/PRNewswire/Invitation+%26amp%3B+Agenda%3A+Orexo+R%26amp%3BD+Day+on+March+24/26123732.html Fri, 06 Mar 2026 11:22:00 -0400 A.05250916 A.08652595 A.38925042 O.00620980 O.00624617 O.02090367 O.03285412 ORX ORX ORX.ST ORXOF ORXOY